|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:2007
gptkb:FDA
|
|
gptkbp:atccode
|
L01 XE05
|
|
gptkbp:bioavailability
|
approximately 25%
|
|
gptkbp:can_be_combined_with
|
gptkb:capecitabine
gptkb:letrozole
|
|
gptkbp:casnumber
|
231277-92-2
|
|
gptkbp:chemical_formula
|
C29 H26 Cl N3 O4 S
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
|
|
gptkbp:clinical_use
|
metastatic breast cancer
locally advanced breast cancer
|
|
gptkbp:contraindication
|
pregnancy
breastfeeding
severe hepatic impairment
|
|
gptkbp:developed_by
|
gptkb:Glaxo_Smith_Kline
|
|
gptkbp:discontinued
|
gptkb:none
|
|
gptkbp:excretion
|
feces
|
|
gptkbp:formulation
|
gptkb:tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Lapatinib
|
|
gptkbp:indication
|
gptkb:HER2-positive_breast_cancer
|
|
gptkbp:interacts_with
|
CYP3 A4 inducers
CYP3 A4 inhibitors
|
|
gptkbp:invention
|
gptkb:2022
|
|
gptkbp:is_monitored_by
|
cardiac function
liver function tests
|
|
gptkbp:lifespan
|
approximately 24 hours
|
|
gptkbp:marketed_as
|
Tykerb
|
|
gptkbp:mechanism_of_action
|
tyrosine kinase inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:nutritional_value
|
approximately 95%
|
|
gptkbp:previous_name
|
yes
|
|
gptkbp:related_products
|
gptkb:pertuzumab
gptkb:neratinib
gptkb:trastuzumab
|
|
gptkbp:research
|
head and neck cancer
other cancers
gastroesophageal cancer
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
rash
hypersensitivity reactions
cardiotoxicity
pulmonary toxicity
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:strength
|
250 mg
|
|
gptkbp:targets
|
HER2 receptor
|
|
gptkbp:used_for
|
gptkb:Oncology
|
|
gptkbp:bfsParent
|
gptkb:EMD_Serono
|
|
gptkbp:bfsLayer
|
5
|